Gate Neurosciences Overview

  • Status
  • Acquired/​Merged

  • Employees
  • 17

Employees

  • Latest Deal Type
  • M&A

Gate Neurosciences General Information

Description

Developer of neuronal therapeutics designed to treat neuropsychiatric and cognitive diseases. The company's therapies are designed to rapidly and safely enhance neuroplasticity and strengthen neuronal connections to restore healthy brain function its drug candidate is currently in Phase 2b clinical trials for Major Depressive Disorder, enabling patients and doctors to have a proper way to treat central nervous system conditions by creating safe, potent, and rapid-acting therapies.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 1210 Waterway Boulevard
  • Indianapolis, IN 46202
  • United States
Primary Industry
Other Pharmaceuticals and Biotechnology
Vertical(s)
Corporate Office
  • 1210 Waterway Boulevard
  • Indianapolis, IN 46202
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Gate Neurosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 27-May-2025 Completed Generating Revenue
5. Early Stage VC 05-Oct-2022 Completed Pre-Clinical Trials
4. Early Stage VC 09-Dec-2021 Completed Pre-Clinical Trials
3. Seed Round 29-Mar-2021 Completed Pre-Clinical Trials
2. Seed Round 11-Jun-2019 $4.5M $4.5M Completed Pre-Clinical Trials
1. University Spin-Out 01-Jan-2018 Completed Pre-Clinical Trials
To view Gate Neurosciences’s complete valuation and funding history, request access »

Gate Neurosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed
To view Gate Neurosciences’s complete cap table history, request access »

Gate Neurosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Gate Neurosciences Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
AbbVie Ventures Corporate Venture Capital Minority
BioCrossroads Venture Capital Minority
Evolution VC Partners Venture Capital Minority
Innoviva Holding Company Minority
Luson BioVentures Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Gate Neurosciences Acquisitions (1)

Gate Neurosciences’s most recent deal was a Merger/Acquisition with Boost Neuroscience. The deal was made on 31-Jan-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Boost Neuroscience 31-Jan-2025 Merger/Acquisition Drug Discovery
To view Gate Neurosciences’s complete acquisitions history, request access »

Gate Neurosciences FAQs

  • Where is Gate Neurosciences headquartered?

    Gate Neurosciences is headquartered in Indianapolis, IN.

  • What is the size of Gate Neurosciences?

    Gate Neurosciences has 17 total employees.

  • What industry is Gate Neurosciences in?

    Gate Neurosciences’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is Gate Neurosciences a private or public company?

    Gate Neurosciences is a Private company.

  • What is Gate Neurosciences’s current revenue?

    The current revenue for Gate Neurosciences is .

  • How much funding has Gate Neurosciences raised over time?

    Gate Neurosciences has raised $45.6M.

  • Who are Gate Neurosciences’s investors?

    AbbVie Ventures, BioCrossroads, Evolution VC Partners, Innoviva, and Luson BioVentures are 5 of 7 investors who have invested in Gate Neurosciences.

  • When was Gate Neurosciences acquired?

    Gate Neurosciences was acquired on 27-May-2025.

  • Who acquired Gate Neurosciences?

    Gate Neurosciences was acquired by Syndeio Biosciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process